EDP1066 Phase 1a/1b study in healthy participants and patients

• Research type

  Research Study

• Full title

  A Phase 1a/1b participant and investigator blind Sponsor unblinded randomized placebo controlled single and multiple ascending dose study of EDP1066 in healthy participants and participants with mild to moderate psoriasis and atopic dermatitis

• IRAS ID

  238864

• Contact name

  Daryl Bendel

• Contact email

  db0065@surrey.ac.uk

• Sponsor organisation

  Evelo Biosciences Inc

• Eudract number

  2017-004337-90

• Duration of Study in the UK

  0 years, 8 months, 0 days

• Research summary

  The primary aim of this study is to assess safety and tolerability of the investigational product EDP1066 in healthy participants and participants with either mild-moderate psoriasis or mild-moderate atopic dermatitis.

  The secondary aim of this study is to establish whether EDP1066 has any effect on the systemic immune system and if there is the potential for clinical benefit.

  EDP1066 is a strain of the bacteria species Lactococcus lactis subsp. Cremoris. It is a naturally occurring organism commonly used in the production of a variety of food products for human consumption (including probiotic formulations, food processing and dairy manufacturing). Experiments in both animal and human models have demonstrated an effect on the immune system.

• REC name

  East of England - Cambridgeshire and Hertfordshire Research Ethics Committee

• REC reference

  17/EE/0494

• Date of REC Opinion

  29 Jan 2018

• REC opinion

  Further Information Favourable Opinion